羟氯喹啉与化疗联合用于癌症的早期临床试验结果
Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer.
作者信息
Poklepovic Andrew, Gewirtz David A
机构信息
Division of Hematology and Oncology; Virginia Commonwealth University; Massey Cancer Center; Richmond, VA USA.
Department of Pharmacology, Toxicology and Medicine; Virginia Commonwealth University; Massey Cancer Center; Richmond, VA USA.
出版信息
Autophagy. 2014 Aug;10(8):1478-80. doi: 10.4161/auto.29428. Epub 2014 Jun 12.
Abstract
The premise of inhibiting autophagy to overcome resistance to chemotherapy has been investigated in 5 clinical phase I trials combining hydroxychloroquine with vorinostat, temsirolimus, temozolomide, or bortezomib. These studies have provided a number of insights relating to the tolerability of the combination treatments. In addition, these studies should provide guidance in the planning and design of future trials to directly determine whether the strategy of autophagy inhibition could prove useful in the treatment of various malignancies.
摘要
在5项将羟氯喹与伏立诺他、替西罗莫司、替莫唑胺或硼替佐米联合使用的临床I期试验中，对抑制自噬以克服化疗耐药性的前提进行了研究。这些研究提供了许多关于联合治疗耐受性的见解。此外，这些研究应为未来试验的规划和设计提供指导，以直接确定抑制自噬策略是否在各种恶性肿瘤治疗中有用。
相似文献
1
Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer.
Autophagy. 2014 Aug;10(8):1478-80. doi: 10.4161/auto.29428. Epub 2014 Jun 12.
2
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Autophagy. 2014 Aug;10(8):1403-14. doi: 10.4161/auto.29231. Epub 2014 May 20.
3
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Autophagy. 2014 Aug;10(8):1391-402. doi: 10.4161/auto.29119. Epub 2014 May 20.
4
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Autophagy. 2014 Aug;10(8):1380-90. doi: 10.4161/auto.29264. Epub 2014 May 20.
5
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Autophagy. 2014 Aug;10(8):1369-79. doi: 10.4161/auto.29118. Epub 2014 May 20.
6
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Oncotarget. 2016 Sep 13;7(37):59087-59097. doi: 10.18632/oncotarget.10824.
7
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Autophagy. 2014 Aug;10(8):1359-68. doi: 10.4161/auto.28984. Epub 2014 May 20.
8
Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Oncotarget. 2015 Jun 30;6(18):16735-45. doi: 10.18632/oncotarget.3793.
9
Autophagy modulation: a target for cancer treatment development.
Cancer Chemother Pharmacol. 2015 Mar;75(3):439-47. doi: 10.1007/s00280-014-2637-z. Epub 2014 Nov 25.
10
Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors.
Int J Mol Sci. 2017 Jun 16;18(6):1279. doi: 10.3390/ijms18061279.
引用本文的文献
1
Innovative horizons: harnessing drug repositioning for targeted therapeutics in colorectal cancer.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 1. doi: 10.1007/s00210-025-04289-3.
2
Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.
Curr Ophthalmol Rep. 2024 Sep;12(3):38-48. doi: 10.1007/s40135-024-00321-6. Epub 2024 Feb 23.
3
Guidelines for the role of autophagy in drug delivery vectors uptake pathways.
Heliyon. 2024 Apr 24;10(9):e30238. doi: 10.1016/j.heliyon.2024.e30238. eCollection 2024 May 15.
4
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2 myeloproliferative neoplasms.
Blood Cancer J. 2023 Jul 10;13(1):106. doi: 10.1038/s41408-023-00875-x.
5
Unmet needs and future perspectives in hydroxychloroquine retinopathy.
Front Med (Lausanne). 2023 Jun 9;10:1196815. doi: 10.3389/fmed.2023.1196815. eCollection 2023.
6
Hydroxychloroquine-induced Retinal Toxicity.
Front Pharmacol. 2023 May 30;14:1196783. doi: 10.3389/fphar.2023.1196783. eCollection 2023.
7
Escape From Cisplatin-Induced Senescence of Hypoxic Lung Cancer Cells Can Be Overcome by Hydroxychloroquine.
Front Oncol. 2022 Jan 21;11:738385. doi: 10.3389/fonc.2021.738385. eCollection 2021.
8
Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells.
Toxicol Res. 2021 Oct 11;38(1):35-44. doi: 10.1007/s43188-021-00109-x. eCollection 2022 Jan.
9
HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights.
Cancers (Basel). 2021 Dec 14;13(24):6280. doi: 10.3390/cancers13246280.
10
ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy.
Sci Transl Med. 2021 Sep 29;13(613):eabd5016. doi: 10.1126/scitranslmed.abd5016.
本文引用的文献
1
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Autophagy. 2014 Aug;10(8):1359-68. doi: 10.4161/auto.28984. Epub 2014 May 20.
2
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Autophagy. 2014 Aug;10(8):1369-79. doi: 10.4161/auto.29118. Epub 2014 May 20.
3
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Autophagy. 2014 Aug;10(8):1391-402. doi: 10.4161/auto.29119. Epub 2014 May 20.
4
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Autophagy. 2014 Aug;10(8):1403-14. doi: 10.4161/auto.29231. Epub 2014 May 20.
5
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Autophagy. 2014 Aug;10(8):1380-90. doi: 10.4161/auto.29264. Epub 2014 May 20.
6
The four faces of autophagy: implications for cancer therapy.
Cancer Res. 2014 Feb 1;74(3):647-51. doi: 10.1158/0008-5472.CAN-13-2966. Epub 2014 Jan 23.
7
Hydrochloroquine retinopathy: characteristic presentation with review of screening.
Clin Rheumatol. 2013 Jun;32(6):895-8. doi: 10.1007/s10067-013-2226-2. Epub 2013 Mar 21.
8
Hydroxychloroquine-induced myopathy.
J Clin Rheumatol. 2010 Jan;16(1):28-31. doi: 10.1097/RHU.0b013e3181c47ec8.
Zotero 插件